title: Design and Synthesis of Dopaminergic Agonists.
abstract: The use of dopaminergic agonists is key in the treatment of Parkinson's disease and related central nervous system (CNS) neurodegenerative disorders. Despite there are a number of commercialized dopaminergic agonists that are currently being used successfully in the first stages of the disease, they often fail to provide sustained clinical benefit for a long period due to the appearance of side-effects such as augmentation, sleepiness, nausea, hypothension, and compulsive behaviors among others. New dopaminergic agonists with less side effects are being developed. These novel compounds offer an alternative when the disease progresses and patients fail to respond to standard dopaminergic treatments or side-effects increased. Chemistry, and in particular chemical synthesis, has played a major role in bringing synthetic dopaminergic agonists to the clinic and continues to be crucial for the development of new and necessary drugs for long-term treatments with less undesired side effects. A number of structural modifications of parent compounds have led to enhanced agonism but also partial agonism or even antagonism of one or more dopamine receptors. In some cases, these activities are accompanied by agonist effect at serotonin receptors which suggests a potential clinical application in the treatment of schizophrenia In this review, chemical synthesis of dopaminergic agents, their affinity, and the corresponding agonist/antagonist effects will be highlighted.
authors.forename: Maria Soledad
authors.initials: MS
authors.lastname: Matute
authors.forename: Rosa
authors.initials: R
authors.lastname: Matute
authors.affiliation: Department of Synthesis and Structure of Biomolecules, Faculty of Sciences, University of Zaragoza, Campus San Francisco, 50009 Zaragoza, Spain. pmerino@unizar.es.
authors.forename: Pedro
authors.initials: P
authors.lastname: Merino
mesh_terms: D001058:Apomorphine / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010617:Phenanthridines / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D011804:Quinolines / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000737:chemistry / Q000378:metabolism
chemical_list: D018491:Dopamine Agonists; D007211:Indoles; D010617:Phenanthridines; D011804:Quinolines; D011954:Receptors, Dopamine; C046649:ropinirole; D001058:Apomorphine